CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bormioli Pharma Bidco S.p.A. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bormioli Pharma Bidco S.p.A.
Corso Magenta 84
Milan, 20123  Italy

Business Summary
Bormioli Pharma Bidco S.p.A. was formed by Triton Partners to facilitate its acquisition of the pharmaceutical business unit of Bormioli Rocco S.p.A. The Company manufactures products that comply with the stringent requirements of the pharmaceutical industry (resistance to heat, sunlight, chemicals, reactivity with content, etc.). It has a successful track record of complying with lengthy and rigorous regulatory approval and customer validation processes, which act as barriers to entry. Customers include global pharmaceutical companies, contract manufacturing organizations, and wholesalers.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
----Yes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
--Yes----

Industries
SIC Code Description
6722 Management investment offices, open-end


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 13, 2022